MedinCell S.A.

LSE:0ACH Stock Report

Market Cap: €491.1m

MedinCell Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Christophe Douat

Chief executive officer

€781.5k

Total compensation

CEO salary percentage38.0%
CEO tenure10.4yrs
CEO ownershipn/a
Management average tenure3.9yrs
Board average tenureless than a year

Recent management updates

Recent updates

CEO Compensation Analysis

How has Christophe Douat's remuneration changed compared to MedinCell's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-€31m

Jun 30 2024n/an/a

-€28m

Mar 31 2024€782k€297k

-€25m

Dec 31 2023n/an/a

-€26m

Sep 30 2023n/an/a

-€26m

Jun 30 2023n/an/a

-€29m

Mar 31 2023€522k€267k

-€32m

Dec 31 2022n/an/a

-€29m

Sep 30 2022n/an/a

-€27m

Jun 30 2022n/an/a

-€26m

Mar 31 2022€329k€258k

-€25m

Dec 31 2021n/an/a

-€22m

Sep 30 2021n/an/a

-€20m

Jun 30 2021n/an/a

-€19m

Mar 31 2021€336k€235k

-€19m

Dec 31 2020n/an/a

-€22m

Sep 30 2020n/an/a

-€26m

Jun 30 2020n/an/a

-€25m

Mar 31 2020€301k€232k

-€24m

Dec 31 2019n/an/a

-€21m

Sep 30 2019n/an/a

-€19m

Jun 30 2019n/an/a

-€19m

Mar 31 2019€244k€192k

-€20m

Dec 31 2018n/an/a

-€17m

Sep 30 2018n/an/a

-€15m

Jun 30 2018n/an/a

-€12m

Mar 31 2018€175k€149k

-€10m

Compensation vs Market: Christophe's total compensation ($USD815.45K) is about average for companies of similar size in the UK market ($USD982.29K).

Compensation vs Earnings: Christophe's compensation has increased whilst the company is unprofitable.

CEO

Christophe Douat (58 yo)

10.4yrs

Tenure

€781,528

Compensation

Mr. Christophe Douat has been the Chief Executive Officer of MedinCell S.A and serves as its Director since September 12, 2024. He served as Chairman of the Management Board at MedinCell S.A until Septembe...

Leadership Team

NamePositionTenureCompensationOwnership
Christophe Douat
Chief Executive Officer & Director10.4yrs€781.53kno data
Franck Pouzache
Chief People Officer & Member of the Management Board4.7yrs€383.09kno data
Stephane Postic
Chief Financial Officer1.3yrsno datano data
Philippe Moyen
Chief Operating Officerno datano datano data
Julie Alimi
General Counsel & Chief Corporate Development Officer3.9yrsno datano data
David Heuze
Head of Corporate & Financial Communications and ESGno datano datano data
Adolfo Lopez-Noriega
Head of Research & Developmentno datano datano data
Sebastien Enault
Chief Business Officer2.9yrsno datano data
Quiterie Beauregard
Head of Global Health Development8.1yrsno datano data
Richard Malamut
Chief Medical Officer2.7yrsno datano data
Stephane Chambaud
Head of Pharmaceutical Operationsno datano datano data
Nicolas Gourgues
Senior Communications Officerno datano datano data

3.9yrs

Average Tenure

Experienced Management: 0ACH's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christophe Douat
Chief Executive Officer & Directorless than a year€781.53kno data
Tone Kvale
Directorless than a year€25.00kno data
Olivier-Sabri Markabi
Directorless than a year€26.50kno data
Philippe Guy
Chairman of the Boardless than a year€28.00kno data
Virginie Lleu
Directorless than a year€25.00kno data
Rachel Almeras
Censorno datano datano data
Elisabeth Kogan
Independent Vice Chairmanless than a year€21.00kno data

0.3yrs

Average Tenure

58yo

Average Age

Experienced Board: 0ACH's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 07:03
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MedinCell S.A. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexandru CogutBryan Garnier & Co
Oscar Haffen LammBryan Garnier & Co
Raghuram SelvarajuH.C. Wainwright & Co.